For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 215,256 | |||
| General and administrative | 100,217 | |||
| Total operating expenses | 315,473 | |||
| Loss from operations | -315,473 | |||
| Interest income | 24,479 | |||
| Interest expense | 7,531 | |||
| Other (expense) income, net | -1,089 | |||
| Total other income, net | 15,859 | |||
| Loss before provision for income taxes | -299,614 | |||
| Provision for income taxes | 1 | |||
| Net loss | -299,615 | |||
| Change in fair value on marketable securities | 393 | |||
| Comprehensive loss | -299,222 | |||
| Basic EPS | -4.66 | |||
| Diluted EPS | -4.66 | |||
| Basic Average Shares | 64,233,814 | |||
| Diluted Average Shares | 64,233,814 | |||
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)